Provided by Tiger Fintech (Singapore) Pte. Ltd.

Metagenomi Technologies, LLC

1.67
+0.15009.87%
Post-market: 1.680.0100+0.60%19:53 EDT
Volume:360.21K
Turnover:605.42K
Market Cap:62.43M
PE:-0.71
High:1.76
Open:1.53
Low:1.52
Close:1.52
Loading ...

Company Profile

Company Name:
Metagenomi Technologies, LLC
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
202
Office Location:
5959 Horton Street,7th Floor,Emeryville,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Directors

Name
Position
Brian C. Thomas
Chief Executive Officer and Director
Jian Irish
President and Chief Operating Officer and Director
Juergen Eckhardt
Director
Sebastián Bernales
Director
Willard Dere
Director

Shareholders

Name
Position
Brian C. Thomas
Chief Executive Officer and Director
Jian Irish
President and Chief Operating Officer and Director
Alan Brooks
Senior Vice President of Preclinical
Pamela Wapnick
Chief Financial Officer
Simon Harnest
Chief Investment Officer and Senior Vice President of Strategy
Christopher T. Brown
Vice President of Discovery
Luis G. Borges
Chief Scientific Officer
Matthew L. Wein
Vice President of Corporate Legal and Compliance and Corporate Secretary
Michael Conway
Vice President of Finance
Sarah Noonberg
Chief Medical Officer
Simren Delaney
Vice President of Intellectual Property and Legal Operations